Shire posts top year-end results and expects earnings to rise again in 2014

13 February 2014
shire-logo-big

Ireland-headquartered drugmaker Shire (LSE: SHP) has recorded a rise in sales and earnings to deliver strong full-year 2013 financial results, pushing the firm’s shares up 1.8% to £31.99 in midday trading.

Product sales came in at $4,757 million, up 12% from $4,253 million in 2012, bringing total revenues to $4,934 million, up 9% from $4,527 million in 2012. The growth in product sales was offset by lower royalties and other revenues.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical